A Study To Evaluate The Safety And Tolerability Of SB-656933-AAA Following Repeated Doses In Healthy Adult Subjects

• Status: Completed
• Trial end date: 2007-09-06
• Target enrollment: 0
• Participant gender: Female

Summary

To assess safety of SB-656933 following repeat dosing for 14 days.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: GlaxoSmithKline
• Treatments: Simvastatin

Criteria

Inclusion Criteria:

• Healthy adult female, aged 18-65 years.

• Female must not be able to have children.

• Non-smoking for the last 6 months.

Exclusion Criteria:

• Any serious medical condition.

• Hepatitis B or C and/or HIV positive.

• Currently on HRT, or other medication except paracetamol.

• Body Mass Index >30.